Botulinum Neurotoxins: Origins and Basic Mechanisms of Action

Pain Practice

Volumn 4, Issue , 2004, Pages S19-S26

  Silberstein, Stephen ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN D; BOTULINUM TOXIN E; BOTULINUM TOXIN F; BOTULINUM TOXIN G; UNCLASSIFIED DRUG;

ANALGESIA; ANTIGENICITY; ANUS FISSURE; ARTICLE; BACTERIAL STRAIN; BLEPHAROSPASM; BOTULISM; CEREBRAL PALSY; CERVICAL DYSTONIA; CLOSTRIDIUM BOTULINUM; DETRUSOR DYSSYNERGIA; DRUG MECHANISM; DRUG PURIFICATION; FOCAL DYSTONIA; FOOT MALFORMATION; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; JAW DISEASE; MIGRAINE; NECK PAIN; NEUROPHYSIOLOGY; NONHUMAN; PAIN; SPASTICITY; STRABISMUS;

EID: 13144262681     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2004.04011.x     Document Type: Article

References (53)

1. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56: 80-99.
2. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker, Inc.; 1994: 3-13.
3. Centers for Disease Control and Prevention. Botulism in the United States, 1899-1996. Handbook for epidemiologists, clinicians, and laboratory workers. Available at: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/botulism.pdf. Accessed July 25, 2003.
4. Van Ermengem E. Classics in infectious diseases: a new anaerobic bacillus and its relation to botulism. Rev Infect Dis. 1979;1: 701-719.
5. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison. Neurology. 1999;53: 1850-1853.
6. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998;129: 221-228.
7. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 2000;82: 427-446.
8. Sakaguchi G, Shunji K, Ohishi I. Structure and function of botulinum toxins. In: Alouf JE, Fehrenbach FJ, Freer JH, Feljaszewicz F, eds. Bacterial Protein Toxins. London: Academic Press, Inc.; 1984: 435-443.
9. DasGupta BR, Sathyamoorthy V. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon. 1984;22: 415-424.
10. Setler PE. Pharmacology of botulinum toxin type B. Eur J Neurol. 2001;8(suppl 4):9-12.
11. Duff JT, Wright GG, Yarinsky A. Activation of Clostridium botulinum type E toxin by trypsin. J Bacteriol. 1956;72: 455-460.
12. Chen F, Kuziemko GM, Stevens RC. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun. 1998;66: 2420-2425.
13. Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med. 1997;40: 317-327.
14. Scott AB. Forward. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker, Inc.; 1994: vii-ix.
15. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45: 1743-1746.
16. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002;18(6 suppl):S177-S181.
17. 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103: 535-544.
18. 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol. 1986;103: 521-534.
19. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Phil Trans R Soc Lond B Biol Sci. 1999;354: 259-268.
20. Binz T, Blasi J, Yamasaki S, et al. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem. 1994;269: 1617-1620.
21. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359: 832-835.
22. Schiavo G, Santucci A, DasGupta BR, et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993;335: 99-103.
23. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365: 160-163.
24. Foran P, Lawrence GW, Shone CC, Foster KA, Dolly JO. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry. 1996;35: 2630-2636.
25. Schiavo G, Malizio C, Trimble WS, et al. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem. 1994;269: 20213-20216.
26. Schiavo G, Shone CC, Bennett MK, Scheller RH, Montecucco C. Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J Biol Chem. 1995;270: 10566-10570.
27. Yamasaki S, Baumeister A, Binz T, et al. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem. 1994;269: 12764-12772.
28. De Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA. 1999;96: 3200-3205.
29. O'Sullivan GA, Mohammed N, Foran PG, Lawrence GW, Dolly JO. Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25: Identification of the minimal essential C-terminal residues. J Biol Chem. 1999;274: 36897-36904.
30. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology. 1997;49: 189-194.
31. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther. 2002;4: 15-18.
32. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett. 1998;256: 135-138.
33. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry. 1998;64: 577-580.
34. Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys. 1995;28: 423-472.
35. Cui M, Chaddock JA, Rubino J, et al. Retargeted clostridial endopeptidase: antinociceptive activity in preclinical models of pain [abstract 21]. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(suppl 2):R16.
36. Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002;18(6 suppl):S133-S141.
37. Rollnik JD, Wohlfarth K, Dengler R, Bigalke H. Neutralizing botulinum toxin type A antibodies: clinical observations in patients with cervical dystonia. Neurol Clin Neurophysiol. 2001;2001: 2-4.
38. ® (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia [abstract]. Mov Disord. 2000;15(suppl 2):30-31.
39. ® Cervical Dystonia Prospective Study Group. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249: 57-63.
40. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53: 1439-1446.
41. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53: 1431-1438.
42. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60: 1186-1188.
43. Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2: 245-247.
44. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113: 400-404.
45. Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve. 1996;19: 488-496.
46. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18(6 suppl):S125-S132.
47. Giladi N. The mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci. 1997;152: 132-135.
48. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(suppl 1):S9-S15.
49. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Hannover, Germany, June 8-12, 2002. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(suppl 2):R7-R50.
50. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38: 245-258.
51. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44: 106-109.
52. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346: 257-270.
53. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol. 2000;15(suppl 3):28-35.